This Case is about COSTS, CRISIS MANAGEMENT
PUBLICATION DATE: July 01, 2010 PRODUCT #: KEL507-HCB-ENG
The case starts with recently designated chairman and interim CEO Garo Armen house on the substantial problems that Elan Corporation, an Irish pharmaceutical business, deals with. About $2 billion in financial obligation that might no longer be pleased in stock will quickly grow, and there are concerns concerning the business’s structure and numerous running issues. Armen is likewise worried about the ethical effects of the business’s failing and hence not being able to establish possibly life-saving medications. The monetary and functional concerns talked about in the case are made complex by Elan’s status as an Irish business with substantial worldwide operations.